Efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB non-small cell lung cancer (periSCOPE): an open-label, single... by Xiangyang Yu, Chujian Huang, Longde Du, Chunguang Wang, Yikun Yang, Xin Yu, Shengcheng Lin, Chenglin Yang, Hongbo Zhao, Songhua Cai, Zhe Wang, Lixu Wang, Xiaotong Guo, Baihua Zhang, Zhentao Yu, Jie He, Kai Ma

“…Summary: Background: The absolute overall survival (OS) improvement with preoperative chemotherapy or chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC) patients is controversial and unsatisfactory. We designed this trial to explore the efficacy and safety of perioperative sintilimab plus platinum-based chemotherapy for potentially resectable stage IIIB NSCLC to facilitate further optimization of this therapeutic strategy. …”
Get full text

Editorial by Michael Rose, Jonathan M. Hoffmann

“…In three contributions (Hoffmann, Nedevska, Unruh), Parfit’s 14-year-old girl is still discussed, and this question remains hotly disputed. For this controversial topic, we have been trying something new: In addition to regular peer-reviewed articles and reviews of selected new publications, we asked several researchers to share their perspectives regarding the C-NIP debate in a short opinion piece. …”
Get full text

60-month follow-up of Long Limb vs. Standard Limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT by Saleem Ansari, Anna Kamocka, Tina Mazaheri, Ibiyemi Ilesanmi, Lara Jimenez-Pacheco, Kleopatra Alexiadou, Joanna Tan, Harvinder Chahal, Krishna Moorthy, Sanjay Purkayastha, Anne Margot Umpleby, Stephen Robert Bloom, Francesco Rubino, Alexander Dimitri Miras, Ahmed Rashid Ahmed, Tricia Tan

“…However, the optimal lengths for the small intestinal limbs remain controversial with variation in practice. A longer biliopancreatic limb length of 150 cm (‘Long Limb’) was hypothesised to better improve glycaemia compared to the standard Roux-en-Y gastric bypass with a biliopancreatic limb of 50 cm (‘Standard Limb’). …”
Get full text

Should the Food and Drug Administration Limit Placebo-Controlled Trials? by Max Goodman, Connor Pedersen

“…Unfortunately, the risk-benefit analysis is often controversial. For example, in 2001, the FDA initially responded positively to a placebo-controlled trial of Surfaxin in infants with acute respiratory distress syndrome in Latin America. …”
Get full text

The application of blockchain with a comparative approach and its impact on risk, flexibility and internal control evaluation by mohammadsadegh aminipoor, HamidReza GholamniaRoshan, azadeh kiapour, Iman Dadashi

“…Extended Abstract Introduction Today, one of the most popular and controversial topics of discussion in accounting and auditing is blockchain technology. …”
Get full text

Comparative Ethics of Modern Payment Models by Jacob Riegler

“…INTRODUCTION Healthcare payment models have always been controversial. Discussions about healthcare payment models broadly include economic, ethical, and medical realms. …”
Get full text

Protecting the Autonomy of Patients with Severe Mental Illness Through Psychiatric Advance Directive Peer-Facilitation by Nicholas Karasik

“…Although general beneficence is controversial in ethics circles, providers can promote the welfare of those they may never meet by relinquishing the responsibility of PAD facilitation to peer-support specialists.[43] In doing so, they remove the possibility of unduly influencing patient preferences, thereby reducing the risk of harm. …”
Get full text